Regarding the IDH status in thalamic tumors, current studies indicate that mutations in the IDH1 and IDH2 genes are relatively uncommon in thalamic gliomas compared to their prevalence in gliomas located in other regions, such as the frontal lobe. This evidence concerns the gene IDH2 and central nervous system cancer.